{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-202610","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.360556+00:00","generated_at":"2026-05-15T00:04:47.210348+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kyverna Therapeutics appoints Nadia Dac as CCO; leads commercial launch for miv-cel in stiff person syndrome","bullets":["Nadia Dac appointed Chief Commercial Officer effective May 4, 2026; has 30+ years experience in neurology and rare disease launches.","She will lead commercial strategy for miv-cel (KYV-101), which is poised for first approval in stiff person syndrome with neuroimmunology expansion.","Previously CCO at Omeros (launched Yartemlea) and Alder (launched Vyepti); held leadership roles at AbbVie, Novartis, Biogen.","Received inducement option for 300,000 shares vesting over 4 years (25% after 1 year, monthly thereafter); exercise at May 4 closing price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202610","json":"https://secwatch.observer/filing/0001193125-26-202610.json","markdown":"https://secwatch.observer/filing/0001193125-26-202610.md","text":"https://secwatch.observer/filing/0001193125-26-202610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/0001193125-26-202610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/kytx-20260415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:04:47.210348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}